OBJECTIVE: To evaluate the effectiveness and safety of artificial intermittent infusion hemodiafiltration (I-HDF) in maintenance hemodialysis (MHD) patients with intradialytic hypotension (IDH), and to determine the optimal infusion dosage. METHODS: This single-center, prospective, self-controlled study included 30 MHD patients with IDH, treated from December 2022 to July 2023. Patients underwent three sessions of I-HDF as treatment group and conventional hemodialysis as control group. Comparisons were made between the two groups regarding changes in blood pressure, hypotension symptoms, changes in body water content, and achievement of infusion doses. RESULTS: 1. The fluctuation amplitude of SBP in the treatment group was 18.96 ± 10.400, while in the control group it was 27.4 ± 11.796. There was a significant difference between the two groups ( CONCLUSION: The artificial I-HDF mode effectively improves the occurrence of IDH. An infusion dose of 150-200 ml is deemed appropriate.